Easy Access to Smoking Cessation for People Receiving Opioid Agonist Therapy Who Are Smoking Tobacco (BAReNikotin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05290025

Recruitment Status : Active, not recruiting

First Posted : March 22, 2022

Last Update Posted : September 25, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Helse Stavanger HF

Helse Vest

University of Bergen

Information provided by (Responsible Party):

Haukeland University Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	October 2023
Estimated Study Completion Date :	December 2026

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Druckrey-Fiskaaen KT, Furulund E, Daltveit JT, Vold JH, Lid TG, Madebo T, Fadnes LT; ATLAS4LAR Study Group. Integration of smoking cessation into standard treatment for patients receiving opioid agonist therapy who are smoking tobacco: protocol for a randomised controlled trial (ATLAS4LAR). Trials. 2022 Aug 17;23(1):663. doi: 10.1186/s13063-022-06560-x.

To Top